HOME > REGULATORY
REGULATORY
- 1,220 Reports of Adverse Events Associated with OTC Drugs Including 24 Deaths Reported in 5 Years: MHLW
August 31, 2012
- DPJ Submits Bill to Form Third-Party Monitoring Organization for Pharmaceutical Affairs
August 30, 2012
- MHLW to Include Creation of Drug Discovery Support Network in FY2013 Draft Budget Request
August 30, 2012
- MHLW Adds Six APIs/10 Products Including Tenelia to NHI Price List
August 29, 2012
- PMDA Eyes World’s First Approval for New Drugs: Chief Executive Kondo
August 28, 2012
- Drug-Dispensing Expenditure Rises 7.9% to 6,513.3 Billion Yen in FY2011: MHLW
August 28, 2012
- PAFSC 2nd Committee to Review 5 Products Including Novartis’s COPD Drug on Sept. 6
August 24, 2012
- Domestic Pharmaceutical Production Up 3.1 %, to Record high 6,987.4 Bil. Yen in 2011
August 24, 2012
- Two Healthcare Provider Reps at CSIMC Criticize Marketing of a Single Drug under Different Brand Names as “Undesirable”
August 24, 2012
- CSIMC Expert Subcommittee Favors Single Index for Efficacy Assessment of Medical Technology
August 24, 2012
- Drug Pricing Subcommittee Presents Negative Views on Reference Pricing System; “Concerns over Patient Copayment Increases”
August 24, 2012
- MHLW to Recommend Use of ReQuip CR Tablets
August 23, 2012
- CSIMC Approves Listing for 6 APIs/10 Products; Peak Sales Projected at 45.6 Billion Yen for Tenelia
August 23, 2012
- Nonpartisan League of Diet Members Aims to Submit Bill during Current Diet Session to Promote Measures against Strokes
August 23, 2012
- Introduction of RMPs Will Enable Clearer Strategies for Post-Marketing Safety: Ms Tawaragi of PFSB
August 23, 2012
- MHLW Budget Request to Focus on Life Innovation: Minister Komiyama
August 22, 2012
- PMDA’s Regulatory Consultation Service Off to Good Start, but More Effort Needed to Promote Face-to-Face Advisory Meetings: Dr Isobe
August 22, 2012
- Healthcare to Receive Priority in FY2013 Draft Budget Request Guidelines
August 21, 2012
- PAFSC’s 1st Committee to Review 7 Products Including Bayer Yakuhin’s AMD Drug on Aug. 31
August 20, 2012
- Subcommittee on Refractory Diseases Prepares to Improve Medical Expenditure Subsidies: Interim Report
August 20, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…